S19--Don’t Sweat It: Navigating the Relationship Between Sweat Chloride & Clinical Outcomes in CF

Chair(s)

• 

  Nicole Hamblett, PhD

  Pediatrics and Biostatistics
  University of Washington
• 

  Edith Zemanick, Aurora, CO, USA

  Pediatrics
  Children's Hospital Colorado, Univ. of Colorado Anschutz Med. Campus

CFTR modulators are rapidly changing care for many people with CF. CFTR modulators reduce sweat chloride but the relationship between sweat chloride and clinical outcomes is complex. In this session, we will discuss the relationship between sweat chloride and CFTR activity, review the use of sweat chloride as a biomarker in clinical trials and its association with clinical outcomes across study populations, and discuss the utility of sweat chloride for clinical monitoring of an individual with CF. Finally, we will discuss implications for future CFTR modulator development in the context of therapeutic goals directed towards further increasing CFTR activity.

Presentations:

• 2:30 PM - 4:30 PM PDT

  S19.1- Is Sweating Enough? Biomarkers of CFTR Function
  

  Speaker: Simon Y. Graeber, MD – Charité - Universitätsmedizin Berlin
• 2:30 PM - 4:30 PM PDT

  S19.2- Relationship Between Genotype, CFTR Activity, and Clinical Phenotype
  

  Speaker: Garry R. Cutting, MD – Johns Hopkins University
• 2:30 PM - 4:30 PM PDT

  S19.3- Sweat Signals: Use of Sweat Chloride in Clinical Trials of CFTR Modulators
  

  Speaker: Rachel Linnemann, MD – Department of Pediatrics, Division of Pulmonology, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine
• 2:30 PM - 4:30 PM PDT

  S19.4- Promise and Pitfalls in Sweat Chloride Use for Clinical Monitoring and Therapeutics Development
  

  Speaker: Edith T. Zemanick, Aurora, CO, USA – Children's Hospital Colorado, Univ. of Colorado Anschutz Med. Campus